Novo Nordisk Unveils Plans to Boost Manufacturing Capacity in North Carolina and Denmark

Novo Nordisk has announced plans to invest approximately $2 billion over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help meet increasing demand for the company’s diabetes drug products. 

Novo Nordisk also announced that it will be initiating a Phase 3a trial for its oral semaglutide, a GLP-1 analogue formulated as a once-daily tablet for the treatment of type 2 diabetes. The facilities in Clayton will produce APIs for semaglutide and a range of Novo Nordisk's current and future GLP-1 and insulin products. Approximately 700 production and engineering positions will be created in Clayton following the expansion. The site already employs more than 700 staff.

Novo Nordisk also plans to open a new production facility in Måløv, Denmark for tableting and packaging of oral semaglutide and future oral products. The investment in Måløv will create an estimated 100 new jobs, according to the company.

The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. The facilities are expected to be operational during 2020.

Source: Novo Nordisk